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ABSTRACT
Addback of donor T cells following T cell-depleted stem cell transplantation (SCT) can accelerate immune
reconstitution and be effective against relapsed malignancy. After haploidentical SCT, a high risk of graft-
versus-host disease (GVHD) essentially precludes this option, unless the T cells are first depleted of alloreac-
tive precursor cells. Even then, the risks of severe GVHD remain significant. To increase the safety of the
approach and thereby permit administration of larger T cell doses, we used a suicide gene, inducible caspase
9 (iCasp9), to transduce allodepleted T cells, permitting their destruction should administration have adverse
effects. We made a retroviral vector encoding iCasp9 and a selectable marker (truncated CD19). Even after
allodepletion (using anti-CD25 immunotoxin), donor T cells could be efficiently transduced, expanded, and
subsequently enriched by CD19 immunomagnetic selection to >90% purity. These engineered cells retained
antiviral specificity and functionality, and contained a subset with regulatory phenotype and function. Activat-
ing iCasp9 with a small-molecule dimerizer rapidly produced >90% apoptosis. Although transgene expression
was downregulated in quiescent T cells, iCasp9 remained an efficient suicide gene, as expression was rapidly
upregulated in activated (alloreactive) T cells. We have demonstrated the clinical feasibility of this approach
after haploidentical transplantation by scaling up production using clinical grade materials.
© 2007 American Society for Blood and Marrow Transplantation
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Donor T cell infusion is an effective strategy for
onferring antiviral and antitumor immunity following
llogeneic stem cell transplantation [1-3]. This can be
articularly useful in T cell-depleted transplantation,
here immune reconstitution is delayed. In haploiden-
ical transplantation, the need to accelerate immune re-
onstitution is most pressing; here, profound immune
eﬁciency as a consequence of vigorous T cell depletion
nd MHC-incompatibility, results in high rates of infec-
ious complications and disease relapse [4,5]. Unfortu-
ately, however, addback of unmanipulated donor T
ells is unlikely to be feasible in the haploidentical setting
ecause graft-versus-host disease (GVHD) can occur ifter addback of as few as 3  104 CD3 cells/kg [6].
his problem can be partially overcome by selective
epletion of alloreactive cells, for example, by using
mmunotoxins directed to activation markers on allo-
eactive cells [7-9]. We, and others, have previously
hown that addback of allodepleted T cells at doses
etween 1 to 8  105 cells/kg is associated with a low
ncidence of GVHD and signiﬁcantly accelerates T cell
ecovery and reconstitutes antiviral immunity [7,8].
owever, disease relapse remains high in these series,
nd because the estimated frequency of tumor-reactive
recursors is 1 to 2 logs less than frequency of viral-
eactive precursors [10,11], much greater dose escalation
s likely required to reconstitute antitumor immunity.
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S.-K. Tey et al.914Although dose escalation of allodepleted T cells
ay be desirable, it may not be safe. The risk of
VHD increases with increasing T cell dose [12], and
he maximum dose that can be safely infused in any
iven individual cannot be predicted with certainty.
nce established, severe GVHD unresponsive to
rontline therapy has a poor prognosis. Hence, al-
hough severe GVHD occurs infrequently, the fact
hat it is unpredictable and may be fatal compromises
ose intensity in all patients. Suicide gene-modiﬁca-
ion of T cells circumvents this biological uncertainty:
ffective T cell doses can be administered to all pa-
ients safe in the knowledge that any GVHD that
evelops can be effectively controlled by activation of
he suicide gene mechanism.
One of the most widely used suicide genes is
erpes simplex virus thymidine kinase (HSVtk). This
nzyme mediates the conversion of ganciclovir to gan-
iclovir triphosphate, which is toxic to dividing cells;
dministration of ganciclovir efﬁciently eliminates
SVtk-modiﬁed T cells and abrogates acute GVHD
aGVHD) [13-15]. Although providing proof of con-
ept of suicide gene therapy, HSVtk has a number of
rawbacks, the most important of which is immuno-
enicity: being a foreign protein, HSVtk is a target for
D4 and CD8 T cell-mediated immune response,
hich results in premature elimination of HSVtk-
odiﬁed cells [16]. Other drawbacks of HSVtk in-
lude restriction of killing to dividing cells, the
nintended elimination of gene-modiﬁed cells when
anciclovir is used for treatment of cytomegalovirus
CMV) reactivation, and ganciclovir resistance re-
ulting from truncated HSVtk formed from cryptic
plice donor and acceptor sites [17].
We investigated the suitability of an alternative sui-
ide gene, inducible caspase 9 (iCasp9) [18]. iCasp9-
ediated suicide is based on conditional dimerization
f pro-apoptotic molecules [18,19] that are con-
tructed from human proteins, and therefore, less
ikely to be immunogenic. The mechanism of killing
llows the safe use of ganciclovir, and is independent
f cell proliferation.
We now show the feasibility of engineering al-
odepleted T cells with an iCasp9 suicide gene trans-
er, and demonstrate the functionality of the modiﬁed
cells, and the scalability of the process.
ATERIALS AND METHODS
eneration of Allodepleted T Cells
Allodepleted cells were generated from healthy
olunteers as previously described [7,20]. In brief,
eripheral blood mononuclear cells (PBMCs) from
ealthy donors were cocultured with irradiated recip-
ent Epstein Barr virus (EBV)-transformed lympho-
lastoid cell lines (LCL) at a responder-to-stimulator patio of 40:1 in serum-free medium (AIM V; Invitro-
en, Carlsbad, CA). After 72 hours, activated T cells
hat expressed CD25 were depleted from the cocul-
ure by overnight incubation in RFT5-SMPT-dgA
mmunotoxin [21]. Allodepletion was considered ade-
uate if the residual CD3CD25 population was
1% and residual proliferation by 3H-thymidine in-
orporation was 10% [7].
lasmid and Retrovirus
SFG.iCasp9.2A.CD19 consists of iCasp9 linked,
ia a cleavable 2A-like sequence, to truncated human
D19 (CD19) (Figure 1A). iCasp9 consists of a
uman FK506-binding protein (FKBP12; GenBank
H002 818) with an F36V mutation, connected via a
er-Gly-Gly-Gly-Ser linker to human caspase 9
CASP9; GenBank NM 001229) [18]. The F36V mu-
ation increases the binding afﬁnity of FKBP12 to the
ynthetic homodimerizer, AP20187 or AP1903 [22].
he caspase recruitment domain (CARD) has been
eleted from the CASP9 sequence because its physi-
logic function has been replaced by FKBP12, and its
emoval increases transgene expression and function
18]. The 2A-like sequence encodes a 20 amino acid
eptide from Thosea Asigna insect virus, which me-
iates 99% cleavage between a glycine and terminal
igure 1. Generation of iCasp9 suicide gene-modiﬁed selectively
llodepleted cells. A, Structure of SFG.iCasp9.2A.CD19. The
ransgene consists of a suicide gene, inducible caspase 9 (iCasp9),
nd a selectable marker, truncated CD19 (CD19), linked by a
A-like sequence, which encodes a cleavable peptide. iCasp9 con-
ists of a drug-binding domain (FKBP12-F36V) connected via a
hort linker (SGGGS) to human caspase 9. B, Overview of the
roduction process. Selective allodepletion was performed by cocul-
uring donor PBMC with recipient EBV-LCL to activate alloreac-
ive cells: activated cells expressed CD25 and were subsequently
liminated by anti-CD25 immunotoxin. The allodepleted cells were
ctivated by OKT3 and transduced with the retroviral vector 48
ours later. Immunomagnetic selection was performed on day 4 of
ransduction; the positive fraction was expanded for a further 4 days
nd cryopreserved.roline residue [23], resulting in 19 extra amino acids
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Caspase 9 Suicide for Allodepleted T Cell Addback 915n the C terminus of iCasp9, and 1 extra proline
esidue in the N-terminus of CD19. CD19 consists
f full-length CD19 (GenBank NM 001770) trun-
ated at amino acid 333 (TDPTRRF), which shortens
he intracytoplasmic domain from 242 to 19 amino
cids, and removes all conserved tyrosine residues that
re potential sites for phosphorylation [24,25].
A stable PG13 clone producing Gibbon ape leu-
emia virus (Gal-V) pseudotyped retrovirus was
ade by transiently transfecting Phoenix Eco cell
ine (ATCC product #SD3444; ATCC, Manassas,
A) with SFG.iCasp9.2A.CD19. This produced
co-pseudotyped retrovirus. The PG13 packaging
ell line (ATCC) was transduced 3 times with Eco-
seudotyped retrovirus to generate a producer line
hat contained multiple SFG.iCasp9.2A.CD19
roviral integrants per cell. Single-cell cloning was
erformed, and the PG13 clone that produced the
ighest titer was expanded and used for vector pro-
uction.
etroviral Transduction
Culture medium for T cell activation and expan-
ion consisted of 45% RPMI 1640 (Hyclone, Logan,
T), 45% Clicks (Irvine Scientiﬁc, Santa Ana, CA)
nd 10% fetal bovine serum (FBS; Hyclone). Allode-
leted cells were activated by immobilized anti-CD3
OKT3; Ortho Biotech, Bridgewater, NJ) for 48
ours before transduction with retroviral vector (Fig-
re 1B). In small-scale experiments, non-tissue cul-
ure-treated 24-well plates (Becton Dickinson, San
ose, CA) were coated with OKT3 1 g/mL for 2 to
hours at 37°C. Allodepleted cells were added at 1
106 cells per well. At 24 hours, 100 U/mL of
ecombinant human interleukin-2 (IL-2) (Proleu-
in; Chiron, Emeryville, CA) was added. Retroviral
ransduction was performed 48 hours after activation.
on-tissue culture-treated 24-well plates were coated
ith 3.5 g/cm2 recombinant ﬁbronectin fragment
CH-296; Retronectin; Takara Mirus Bio, Madison,
I) and the wells loaded twice with retroviral vector-
ontaining supernatant at 0.5 mL per well for 30
inutes at 37°C, following which OKT3-activated
ells were plated at 5  105 cells per well in fresh
etroviral vector-containing supernatant and T cell
ulture medium at a ratio of 3:1, supplemented with
00 U/mL IL-2. Cells were harvested after 2 to 3 days
nd expanded in the presence of 50 U/ml IL-2.
caling-Up Production of Gene-Modified
llodepleted Cells
Scale-up of the transduction process for clinical ap-
lication used non-tissue culture-treated T75 ﬂasks
Nunc, Rochester, NY), which were coated with 10 mL
f OKT3 1 g/mL or 10 mL of ﬁbronectin 7 g/mL at
°C overnight. We also used ﬂuorinated ethylene pro- 2ylene bags corona-treated for increased cell adherence
2PF-0072AC, American Fluoroseal Corporation,
aithersburg, MD). Allodepleted cells were seeded in
KT3-coated ﬂasks at 1 106 cells/mL; 100U/ml IL-2
as added the next day. For retroviral transduction,
etronectin-coated ﬂasks or bags were loaded once with
0 mL of retroviral vector-containing supernatant for 2
o 3 hours. OKT3-activated T cells were seeded at 1 
06 cells/mL in fresh retroviral vector-containing me-
ium and T cell culture medium at a ratio of 3:1, sup-
lemented with 100U/ml IL-2. Cells were harvested the
ollowing morning and expanded in tissue culture-
reated T75 or T175 ﬂasks in culture medium supple-
ented with 50 to 100 U/ml IL-2 at a seeding density of
to 8  105 cells/mL.
D19 Immunomagnetic Selection
Immunomagnetic selection for CD19 was per-
ormed 4 days after transduction. Cells were labeled
ith paramagnetic microbeads conjugated to mono-
lonal mouse antihuman CD19 antibodies (Miltenyi
iotech, Auburn, CA) and selected on MS or LS
olumns in small-scale experiments and on a Clini-
acs Plus automated selection device in large-scale
xperiments. CD19-selected cells were expanded for a
urther 4 days and cryopreserved on day 8 post trans-
uction. These cells were referred to as “gene-modi-
ed allodepleted cells.”
mmunophenotyping and Pentamer Analysis
Flow cytometric analysis (FACSCalibur and
ellQuest software; Becton Dickinson) used the fol-
owing antibodies: CD3, CD4, CD8, CD19, CD25,
D27, CD28, CD45RA, CD45RO, CD56, and
D62L. CD19-PE (Clone 4G7; Becton Dickinson)
as found to give optimum staining and was used in
ll analyses. Nontransduced control was used to set
he negative gate for CD19. An HLA-pentamer,
LA-B8-RAKFKQLL (Proimmune, Springﬁeld,
A) was used to detect T cells recognizing an epitope
rom EBV lytic antigen (BZLF1). HLA-A2-NLVPM-
ATV pentamer was used to detect T cells recogniz-
ng an epitope from CMV-pp65 antigen.
nterferon- ELISPOT Assay for Antiviral
esponse
Interferon- ELISPOT for assessment of re-
ponses to EBV, CMV, and adenovirus antigens was
erformed as previously described [20]. Gene-modi-
ed allodepleted cells cryopreserved at 8 days post
ransduction were thawed and rested overnight in
omplete medium without IL-2 prior to use as re-
ponder cells. Cryopreserved PBMCs from the same
onor were used as comparators. Responder cells were
lated in duplicate or triplicate in serial dilutions of
 105, 1 105, 5 104, and 2.5 104 cells per well.
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S.-K. Tey et al.916timulator cells were plated at 1  105 per well. For
esponse to EBV, donor-derived EBV-LCLs irradi-
ted at 40 Gy were used as stimulators. For response
o adenovirus, donor-derived activated monocytes in-
ected with Ad5f35 adenovirus were used. In brief,
onor PBMCs were plated in X-Vivo 15 (Cambrex,
alkersville, MD) in 24-well plates overnight, har-
ested the next morning, infected with Ad5f35 at mul-
iplicities of infection (MOI) of 200 for 2 hours,
ashed, irradiated at 30 Gy, and used as stimulators.
or anti-CMV response, a similar process using
d5f35 adenovirus encoding the CMV pp65 trans-
ene (Ad5f35-pp65) at an MOI of 5000 was used.
peciﬁc spot-forming units (SFU) were calculated by
ubtracting SFU from responder-alone and stimula-
or-alone wells from test wells. Response to CMV was
he difference in SFU between Ad5f35-pp65 and
d5f35 wells.
BV-Specific Cytotoxicity
Gene-modiﬁed allodepleted cells were stimulated
ith 40 Gy-irradiated donor-derived EBV-LCL at a
esponder:stimulator ratio of 40:1. After 9 days, the
ultures were restimulated at a responder:stimulator
atio of 4:1. Restimulation was performed weekly as
ndicated. After 2 or 3 rounds of stimulation, cytotox-
city was measured in a 4-hour 51Cr-release assay,
sing donor EBV-LCL as target cells and donor
KT3 blasts as autologous controls. NK activity was
nhibited by adding 30-fold excess of cold K562 cells.
nduction of Apoptosis with Chemical Inducer of
imerization, AP20187
Suicide gene functionality was assessed by adding
small molecule synthetic homodimerizer, AP20187
Ariad Pharmaceuticals; Cambridge, MA), at 10 nM
nal concentration the day following CD19 immuno-
agnetic selection. Cells were stained with annexin V
nd 7-amino-actinomycin (7-AAD) (BD Pharmingen,
an Diego, CA) at 24 hours and analyzed by ﬂow
ytometry. Cells negative for both Annexin V and
-AAD were considered viable, cells that were annexin
positive were apoptotic, and cells that were both
nnexin V and 7-AAD positive were necrotic. The
ercentage killing induced by dimerization was cor-
ected for baseline viability as follows: Percentage
illing  100% 	 (%Viability in AP20187-treated
ells 
 %Viability in nontreated cells).
ssessment of Transgene Expression following
xtended Culture and Reactivation
Cells were maintained in T cell medium contain-
ng 50 U/ml IL-2 until 22 days after transduction. A
ortion of cells was reactivated on 24-well plates
oated with 1 g/mL OKT3 and 1 g/mL anti-CD28
Clone CD28.2, BD Pharmingen) for 48 to 72 hours. cD19 expression and suicide gene function in both
eactivated and nonreactivated cells were measured on
ay 24 or 25 post transduction.
In some experiments we also cultured the cells for
weeks post transduction but simulated them with 30
y-irradiated allogeneic PBMC at responder:stimula-
or ratio of 1:1. After 4 days of coculture, a portion of
ells was treated with 10 nM AP20187. Killing was
easured by annexin V/7-AAD staining at 24 hours,
nd the effect of dimerizer on bystander virus-speciﬁc
cells was assessed by pentamer analysis on
P20187-treated and untreated cells.
egulatory T Cells
We analyzed CD4, CD25, and Foxp3 expression
n gene-modiﬁed allodepleted cells using ﬂow cytom-
try. For human Foxp3 staining we used the eBio-
cience (San Diego, CA) staining set with an appro-
riate rat IgG2a isotype control. These cells were
ostained with surface CD25-FITC and CD4-PE.
unctional analysis was performed by coculturing
D425 cells selected after allodepletion and gene
odiﬁcation with autologous PBMC labeled with car-
oxyﬂuorescein diacetate N-succinimidyl ester (CFSE).
D425 selection was performed by ﬁrst depleting
D8 cells using anti-CD8 microbeads (Miltenyi
iotec, Auburn, CA), followed by positive selection
sing anti-CD25 microbeads (Miltenyi Biotec).
FSE-labeling was performed by incubating autolo-
ous PBMC at 2  107/mL in phosphate-buffered
aline (PBS) containing 1.5 M CFSE for 10 minutes.
he reaction was stopped by adding an equivalent
olume of FBS and incubating for 10 minutes at 37°C.
ells were washed twice before use. We stimulated
FSE-labeled PBMCs with OKT3 500 ng/mL and 40
y-irradiated allogeneic PBMC feeders at PBMC:
llogeneic feeders ratio of 5:1. We cultured the cells
ith or without an equal number of autologous
D425 gene-modiﬁed allodepleted cells. After 5
ays of culture, cell division was analyzed by ﬂow
ytometry; CD19 was used to gate out non-CFSE-
abeled CD4CD25 gene-modiﬁed T cells.
tatistical Analysis
Paired, 2-tailed Student’s t-test was used to deter-
ine the statistical signiﬁcance of differences between
amples. All data are represented as mean  1 stan-
ard deviation.
ESULTS
electively Allodepleted T Cells Could Be
fficiently Transduced with iCasp9 and Expanded
Selective allodepletion was performed in accor-
ance with procedures established for our recently
ompleted clinical protocol [7], by coculturing 3/6 to
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Caspase 9 Suicide for Allodepleted T Cell Addback 917/6 HLA-mismatched PBMC and LCL. RFT5-
MPT-dgA immunotoxin was applied after 72 hours
f coculture and reliably produced allodepleted cells
ith 10% residual proliferation (mean: 4.5% 
.8%; range: 0.74%-9.1%; 10 experiments) and con-
aining 1% residual CD3CD25 cells (mean:
.23%  0.20%; range: 0.06%-0.73%; 10 experi-
ents), thereby fulﬁlling the release criteria for selec-
ive allodepletion, and serving as starting materials for
ubsequent manipulation.
Allodepleted cells activated on immobilized
KT3 for 48 hours could be efﬁciently transduced
ith Gal-V pseudotyped retrovirus vector encoding
FG.iCasp9.2A.CD19. Transduction efﬁciency as-
essed by FACS analysis for CD19 expression 2 to 4
ays after transduction was 53%  8%, with compa-
able results for small-scale (24-well plates) and large-
cale (T75 ﬂasks) transduction (55%  8% versus
0%  10% in 6 and 4 experiments, respectively).
ell numbers contracted in the ﬁrst 2 days following
KT3 activation such that only 61%  12% (range:
5%-80%) of allodepleted cells were recovered on the
ay of transduction (Figure 2). Thereafter, the cells
igure 2. Allodepleted cells could be successfully expanded follow-
ng transduction. Filled diamond denotes large-scale experiments
erformed in ﬂasks and bags (n 3), open circle denotes small-scale
xperiments performed in 24-well plates (n 5). Error bars indicate
tandard deviation.
igure 3. Suicide gene-modiﬁed cells could be enriched to high puri
as performed on day 4 post transduction using CliniMacs Plus aut
fter immunomagnetic selection. Filled lines indicate CD19-PE; unﬁlledhowed signiﬁcant expansion, with a mean 94  46-
old expansion (range: 40-153) over the subsequent 8
ays, resulting in a net 58  33-fold expansion. Cell
xpansion in both small- and large-scale experiments
as similar, with net expansion of 45 29-fold (range:
5-90) in 5 small-scale experiments and 79  34-fold
range: 50-116) in 3 large-scale experiments.
CD19 Enables Efficient and Selective
nrichment of Transduced Cells on
mmunomagnetic Columns
The efﬁciency of suicide gene activation will de-
end not only on the functionality of the suicide gene
tself, but also on the selection system used to enrich
or gene-modiﬁed cells. Because of limitations of se-
ectable markers currently in use, we investigated
hether CD19 enabled the selection of gene-modi-
ed cells with sufﬁcient purity and yield, and whether
election had any deleterious effects on subsequent
ell growth. Small-scale selection was performed ac-
ording to manufacturer’s instruction; however, we
ound that large-scale selection was optimum when we
sed 10 L of CD19 microbeads per 1.3  107 cells.
ACS analysis was performed at 24 hours after immu-
omagnetic selection to minimize interference from
nti-CD19 microbeads. The purity of the cells after
mmunomagnetic selection was consistently 90%:
ean percentage of CD19 cells was 98.3%  0.5%
n  5) in small-scale selections and 97.4%  0.9%
n  3) in large-scale CliniMacs selections (Figrue 3).
he absolute yield of small- and large-scale selections
ere 31%  11% and 28%  6%, respectively; after
orrection for transduction efﬁciency, the mean re-
overy of transduced cells was 54%  14% in small-
cale and 72%  18% in large-scale selections. The
election process did not have any discernable delete-
ious effect on subsequent cell expansion: in 4 exper-
ments, the mean cell expansion over 3 days following
D19 immunomagnetic selection was 3.5-fold for the
D19 positive fraction versus 4.1-fold for nonselected
D19 immunomagnetic selection. CD19 immunomagnetic selection
selection device. Shown here are FACS analyses performed 2 daysty by C
omatedlines indicate isotype control.
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S.-K. Tey et al.918ransduced cells (p  .34) and 3.7-fold for nontrans-
uced cells (P  .75).
mmunophenotype of Gene-Modified
llodepleted Cells
We immunophenotyped the ﬁnal cell product
gene-modiﬁed allodepleted cells that had been cryo-
reserved 8 days after transduction). This ﬁnal cell
roduct contained both CD4 and CD8 cells, with
D8 cells predominant (Table 1) at 62%  11%
D8 versus 23% 8% CD4. The majority of cells
ere CD45RO and had the surface immunopheno-
ype of effector memory T cells. Expression of mem-
ry markers, including CD62L, CD27, and CD28,
as heterogeneous. Approximately 24% of cells ex-
ressed CD62L, a lymph node-homing molecule pre-
ominantly expressed on central memory cells.
ene-Modified Allodepleted Cells Retained
ntiviral Repertoire and Functionality
The ability of end-product cells to mediate anti-
iral immunity was assessed by interferon- ELIS-
OT, cytotoxicity assay, and pentamer analysis. These
ryopreserved gene-modiﬁed allodepleted cells were
sed in all analyses, because they were representative
f the product we propose to administer in the clinical
tudy. Interferon- secretion in response to adenovi-
us, CMV, or EBV antigens presented by donor cells
as preserved, although there was a trend towards
educed anti-EBV response in gene-modiﬁed allode-
leted cells versus unmanipulated PBMC (Figure 4A).
Cytotoxicity was assessed using donor-derived
BV-LCL as targets. Gene-modiﬁed allodepleted
ells that had undergone 2 or 3 rounds of stimulation
ith donor-derived EBV-LCL could efﬁciently lyse
irus-infected autologous target cells (Figure 4B). Be-
ause EBV-LCLs were used as antigen-presenting
ells during selective allodepletion, it was possible that
able 1. Comparison of Immunophenotype of Gene-Modiﬁed Allodeplet
Unmanipulated PBMC
(mean %  SD)
cells: Total CD3 82  6
CD3 4 54  5
CD3 8 26  9
K cells: CD3 56 6  3
emory phenotype
CD45RA 66  3
CD45RO 26  2
CD45RA CD62L 19  1
CD45RA CD62L 9  1
CD27 CD28 67  7
CD27 CD28 7  3
CD27 CD28 4  1
CD27 CD28 22  8
S indicates not signiﬁcant; PBMC, peripheral blood mononucleaBV-speciﬁc T cells could be signiﬁcantly depleted ahen the donor and recipient were haploidentical. We
herefore included 3 experiments using unrelated
LA-haploidentical donor-recipient pairs, and
howed that cytotoxicity against donor-derived EBV-
CL was retained. The results were corroborated by
entamer analysis for T cells recognizing HLA-B8-
AKFKQLL, an EBV lytic antigen (BZLF1) epitope, in
informative donors following allodepletion against
LA-B8 negative haploidentical recipients (Figrue 4C).
he RAK-pentamer positive population was retained
nd could expand following stimulation with donor
BV-LCL. Together, these results provided evidence
hat gene-modiﬁed allodepleted cells retained signiﬁcant
ntiviral functionality.
egulatory T Cells in the Gene-Modified
llodepleted Cell Population
We used ﬂow cytometry and functional analysis to
iscover whether regulatory T cells were retained in
ur allodepleted, gene-modiﬁed, T cell product. We
ound a CD4CD25Foxp3 population (Figure 5A),
nd following immunomagnetic separation, the
D4CD25 enriched fraction demonstrated sup-
ressor function when cocultured with CFSE-labeled
utologous PBMC in the presence of OKT3 and al-
ogeneic feeders (Figure 5B). Hence, allodepleted T
ells may reacquire regulatory phenotype even after
xposure to a CD25-depleting immunotoxin.
ene-Modified Allodepleted Cells Were Efficiently
nd Rapidly Eliminated by Addition of Chemical
nducer of Dimerization
The day following immunomagnetic selection,
0 nM of the chemical inducer of dimerization,
P20187, was added to induce apoptosis, which ap-
eared within 24 hours. FACS analysis with annexin V
nd 7-AAD staining at 24 hours showed that only
.5%  2.5% of AP20187-treated cells remained vi-
and Unmanipulated PBMC
Gene-Modified Allodepleted Cells
(mean %  SD) P-Value
95  6 NS
23  8 <.01
62  11 <.001
2  1 NS
10  5 <.001
78  7 <.001
24  7 NS
64  7 <.001
19  9 <.001
9  4 NS
19  8 <.05
53  18 <.05
D, standard deviation.ed Cellsble, whereas 81.0%  9.0% of untreated cells were
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Caspase 9 Suicide for Allodepleted T Cell Addback 919iable (Figure 6A). Killing efﬁciency after correction
or baseline viability was 92.9%  3.8%. Large-scale
D19 selection produced cells that were killed with
imilar efﬁciency as small-scale selection: mean viabil-
ty with and without AP20187, and percentage killing,
n large and small scale were 3.9%, 84.0%, and 95.4%
n  3), and 6.6%, 79.3%, and 91.4% (n  5), respec-
ively. AP20187 was nontoxic to nontransduced cells:
iability with and without AP20187 were 86%  9%
nd 87%  8%, respectively (n  6).cigure 4. Gene-modiﬁed allodepleted cells retained antiviral rep-
rtoire and functionality. A, Interferon- secretion in response to
iral antigens was assessed by ELISPOT in 4 pairs of unmanipu-
ated PBMC and gene-modiﬁed allodepleted cells (GMAC). Ade-
ovirus and CMV antigens were presented by donor-derived acti-
ated monocytes through infection with Ad5f35 null vector and
d5f35-pp65 vector, respectively. EBV antigens were presented by
onor EBV-LCL. Number of spot-forming units (SFU) were cor-
ected for stimulator- and responder-alone wells. Only 3 of 4
onors were evaluable for CMV response, 1 seronegative donor was
xcluded. Horizontal bars  median. B, Cytotoxicity assay. Gene-
odiﬁed allodepleted cells were stimulated with donor EBV-LCL
or 2 or 3 cycles. 51Cr release assay was performed using donor-
erived EBV-LCL and donor OKT3 blasts as targets. NK activity
as blocked with 30-fold excess cold K562. Left panel shows results
rom 5 independent experiments using totally or partially mismatched
onor-recipient pairs. Right panel shows results from 3 experiments
sing unrelated HLA haploidentical donor-recipient pairs. Error
ars indicate standard deviation. C, The frequency of T cells spe-
iﬁc for HLA-B8- RAKFKQLL, an epitope from an EBV lytic
ntigen (BZLF1), was analyzed. Unmanipulated PBMC were used
s comparators. The RAK-pentamer positive population was re-
ained in gene-modiﬁed allodepleted cells and could be expanded
ollowing several rounds of in vitro stimulation with donor-derived
BV-LCL. Percentages indicate percentage of pentamer positiveigure 5. Regulatory T cells could be isolated from gene-modiﬁed
nd-product cells despite initial allodepletion using CD25-immuno-
oxin. A, Foxp3 expression. A small population of CD4
D25Foxp3 cells was detectable. B, Functional assay. Donor-de-
ived PBMC was labeled with CFSE and stimulated with OKT3 and
llogeneic feeders. CD4CD25 cells were immunomagnetically se-
ected from allodepleted gene-modiﬁed cell population and added at
:1 ratio to test wells. Flow cytometry was performed after 5 days.
ene-modiﬁed T cells were gated out by CD19 expression. The
ddition of CD4CD25 gene-modiﬁed cells (bottom panel) signiﬁ-ells within CD8 population.
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S.-K. Tey et al.920ransgene Expression and Function Decreased
ith Extended Culture But Were Restored upon
ell Reactivation
To assess the stability of transgene expression and
unction, we maintained cells in T cell culture me-
igure 6. Gene-modiﬁed allodepleted cells were rapidly and efﬁcie
iminished with extended culture but were completely restored up
ere treated with 10 nM dimerizer (AP20187). FACS analysis for an
ells are indicated in the plots. AP20187 resulted in 90% killing o
epresentative of 3 large-scale experiments. B, Transduced cells wer
/mL). A portion of cells was then reactivated with OKT3/anti-CD
nd suicide gene function was assessed by treatment with 10 nM AP
fter CD19 selection) and day 24 post transduction, with or witho
election was performed after OKT3/aCD28 activation to further e
.05 when compared to cells from day 5 post transduction. C, Rep
ctivation on suicide gene function. Greater than 90% of activatedium and low-dose IL-2 (50 U/mL) until 24 days after gransduction. By day 24, surface CD19 expression fell
rom 98%  1% to 88%  4% (P  .05) with a
arallel decrease in mean ﬂuorescence intensity (MFI)
rom 793% 128 to 478 107 (P .05) (Figure 6B).
imilarly, there was a signiﬁcant reduction in suicide
iminated by AP20187. Transgene expression and killing efﬁciency
ell reactivation. A, The day after immunomagnetic selection, cells
and 7-AAD was performed at 24 hours. The percentages of viable
uced cells but had no effect on nontransduced controls. Results are
tained in culture for 22 days post transduction in low dose IL-2 (50
19 expression was analyzed by ﬂow cytometry 48 to 72 hours later,
Results shown are for cells from day 5 post transduction (ie, 1 day
2 hours of reactivation (5 experiments). In 2 experiments, CD25
ctivated cells. Error bars represent standard deviation. *Indicates P
tive FACS plots showing the effect of extended culture and T cell
positive T cells were killed by AP20187.ntly el
on T c
nexin V
f transd
e main
28. CD
20187.
ut 48-7
nrich a
resentaene function: residual viability was 19.6%  5.6%
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Caspase 9 Suicide for Allodepleted T Cell Addback 921ollowing treatment with AP20187; after correction
or baseline viability of 54.8%  20.9%, this equated
o a killing efﬁciency of only 63.1%  6.2%.
To discover whether the decrease in transgene
xpression with time resulted in reduced transcrip-
ion following T cell quiescence or to elimination of
ransduced cells, we reactivated a portion of cells on
ay 22 post transduction with OKT3 and anti-
D28 antibody. At 48 to 72 hours (day 24 or 25
ost transduction), OKT3/aCD28-reactivated cells
ad signiﬁcantly higher transgene expression than
onreactivated cells. CD19 expression increased
rom 88%  4% to 93%  4% (P  .01) and CD19
FI increased from 478  107 to 643  174 (P 
01). More importantly, suicide gene function also
ncreased signiﬁcantly from 63.1%  6.2% killing
fﬁciency to 84.6%  8.0% (P  .01). Furthermore,
illing efﬁciency was completely restored if the cells
ere immunomagnetically sorted for the activation
arker CD25: killing efﬁciency of CD25 positive cells
as 93.2%  1.2%, which was the same as killing
fﬁciency on day 5 post transduction (93.1%  3.5%)
Figure 6C). Killing of the CD25 negative fraction
as 78.6%  9.1%.
Of note, virus-speciﬁc T cells are spared when
imerizer is used to deplete gene-modiﬁed cells that
ave been reactivated with allogeneic PBMC, rather
han by nonspeciﬁc mitogenic stimuli. After 4 days
eactivation with allogeneic cells, Figure 7A and B
how that treatment with AP20187 spares (and
hereby enriches) viral reactive subpopulations, as
easured by the proportion of T cells reactive with
LA pentamers speciﬁc for peptides derived from
igure 7. Virus-speciﬁc T cells were partially retained after treatme
ere maintained in culture for 3 weeks post transduction to allow t
or 4 days, following which a portion was treated with 10nM AP2018
ere quantiﬁed by pentamer analysis before allostimulation, after a
he percentage of viral-speciﬁc T cells decreased after allostimulatio
nd preferentially retained.BV and CMV. TISCUSSION
We have demonstrated the feasibility of engineer-
ng allogeneic T cells with two distinct safety mecha-
isms, selective allodepletion and suicide gene modi-
cation. In combination, these modiﬁcations should
nable addback of substantial numbers of T cells with
ntiviral and antitumor activity, even after haploiden-
ical transplantation. Our data show that the suicide
ene, iCasp9, functions efﬁciently (90% apoptosis
fter treatment with dimerizer) and that down-mod-
lation of transgene expression that occurred with
ime was rapidly reversed upon T cell activation, as
ould occur when alloreactive T cells encountered
heir targets. We also showed that CD19 was a
uitable selectable marker that enabled efﬁcient and
elective enrichment of transduced cells to 90% pu-
ity, and that these manipulations had no discernable
ffects on the immunologic competence of the engi-
eered T cells with retention of antiviral activity, and
egeneration of a CD4CD25Foxp3 population
ith Treg activity.
Given that the overall functionality of suicide
enes depends on both the suicide gene itself and the
arker used to select the transduced cells, translation
nto clinical use requires optimization of both compo-
ents, and of the method used to couple expression of
he two genes. The two most widely used selectable
arkers in clinical practice each have drawbacks.
eomycin phosphotransferase (neo) encodes a poten-
ially immunogenic foreign protein and requires a
-day culture in selection medium, which not only
ncreases the complexity of the system, but is also
otentially damaging to virus-speciﬁc T cells [26].
lostimulated cells with dimerizer. Gene-modiﬁed allodepleted cells
e down-modulation. Cells were stimulated with allogeneic PBMC
frequency of A, EBV-speciﬁc T cells, and B, CMV-speciﬁc T cells
ulation, and after treatment of allostimulated cells with dimerizer.
owing treatment with dimerizer, viral-speciﬁc T cells were partiallynt of al
ransgen
7. The
llostim
n. Follhe most widely used surface selection marker is
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S.-K. Tey et al.922LNGFR, but a recent report of leukemia in a mouse
odel raises concerns regarding its oncogenic poten-
ial [27], despite its apparent clinical safety [28]. Fur-
hermore, LNGFR selection is not widely available,
ecause it is used almost exclusively in gene therapy. A
umber of alternative selectable markers have been
uggested. CD34 has been well-studied in vitro
29,30], but the steps required to optimize a system
esigned primarily for selection of rare hematopoietic
rogenitors and, more critically, the potential for al-
ered in vivo T cell homing [31], make CD34 subop-
imal for our purpose. As an alternative marker, we
sed CD19, because clinical grade CD19 selection is
eadily available as a method for B cell depletion of
tem cell autografts. We demonstrated that CD19
nrichment could be performed with high purity and
ield and, more importantly, the selection process had
o discernable effect on subsequent cell growth and
unctionality.
The effectiveness of suicide gene activation in
CD19-selected iCasp9 cells compared very favorably
o that of neo- or LNGFR-selected cells transduced
o express the HSVtk gene. The earlier generations of
SVtk constructs provided 80%-90% suppression of
H-thymidine uptake [14,32,33] and showed similar
eduction in killing efﬁciency upon extended in vitro
ulture [33], but were nonetheless clinically efﬁca-
ious. Complete resolution of both aGVHD and
hronic GVHD (cGVHD) has been reported with as
ittle as 80% in vivo reduction in circulating gene-
odiﬁed cells. These data supported the hypothesis
hat transgene down-modulation seen in vitro is un-
ikely to be an issue because activated T cells respon-
ible for GVHD will upregulate suicide gene expres-
ion and will therefore be selectively eliminated in
ivo [14]. Whether this effect is sufﬁcient to allow
etention of virus- and leukemia-speciﬁc T cells in
ivo remains to be tested in a clinical setting. By
ombining in vitro selective allodepletion prior to
uicide gene modiﬁcation, we hope that the need to
ctivate the suicide gene mechanism will be signiﬁ-
antly reduced, thereby maximizing the beneﬁts of
ddback T cell.
The high efﬁciency of iCasp9-mediated suicide
een in vitro has been replicated in vivo. In an SCID
ouse-human xenograft model, 99% of iCasp9-
odiﬁed T cells were eliminated after a single dose of
imerizer [18]. Safety testing has been performed on
ealthy human volunteers using AP1903, which has
xtremely close functional and chemical equivalence
o AP20187, and would be used in a proposed clinical
pplication. Maximal plasma level of 10 to 1275
g/mL AP1903 (equivalent to 7 to 892 nM) was at-
ained over a 0.01 mg/kg to 1.0 mg/kg dose range
dministered as a 2-hour intravenous infusion [34].
here were no signiﬁcant adverse effects. After allow-ng for rapid plasma redistribution, the concentration wf dimerizer used in vitro remains readily achievable
n vivo.
We believe iCasp9 will prove to have several ad-
antages over HSVtk, including the ability to use
anciclovir and related drugs without causing inadver-
ent T cell destruction, and a reduced risk of destruc-
ive immune responses against transduced cells be-
ause the iCasp9 is almost entirely human derived.
lthough both our selectable marker (CD19) and
ur suicide gene (iCasp9) are of human origin, one
otential limitation of our approach is that linkage of
xpression of the selectable marker to the suicide gene
ses a 2A-like cleavable peptide that is of nonhuman
rigin. However, this product is only 20 amino acids
ong, and is therefore less likely to be immunogenic than
ntirely nonhuman proteins such as neo or HSVtk.
It is essential to deﬁne the culture conditions that
re optimal for maintaining the immunologic compe-
ence of suicide gene-modiﬁed T cells, because phe-
otype, repertoire, and functionality can all be af-
ected by the stimulation used for polyclonal T cell
ctivation [35,36], the method for selection of trans-
uced cells [26], and duration of culture [37]. The
ddition of CD28 costimulation and the use of cell-
ized paramagnetic beads to generate gene modiﬁed-
ells that more closely resemble unmanipulated
BMC in terms of CD4:CD8 ratio, and expression of
emory subset markers, including lymph node hom-
ng molecules CD62L and CCR7, have been proposed
s methods for improving the in vivo functionality of
ene-modiﬁed T cells [35,36]. CD28 costimulation
as also been reported to increase the efﬁciency of
etroviral transduction and expansion [35,36]. Inter-
stingly, however, we found that the addition of CD28
ostimulation had no impact on transduction of al-
odepleted cells (data not shown), and the degree of
ell expansion seen in our study was higher compared
o the anti-CD3 alone arm in these studies. Further-
ore, iCasp9-modiﬁed allodepleted cells retained sig-
iﬁcant antiviral functionality, and approximately a
uarter retained CD62L expression. There was also
egeneration of CD4CD25Foxp3 regulatory T
ells. The allodepleted cells we used as starting mate-
ial for T cell activation and transduction may have
een less sensitive to the addition of anti-CD28 anti-
ody as costimulation. CD25-depleted PBMC/EBV-
CL cocultures contained T cells and B cells that
lready express CD86 at signiﬁcantly higher levels
han unmanipulated PBMC (data not shown) and may
hemselves provide costimulation. In addition, it has
een reported that depletion of CD25 regulatory T
ells prior to polyclonal T cell activation with anti-
D3 enhances the immunological competence of the
nal T cell product [37]. To minimize the effect of in
itro culture and expansion on functional competence,
e used a relatively brief culture period whereby cells
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Caspase 9 Suicide for Allodepleted T Cell Addback 923ere expanded for a total of 8 days post transduction
ith CD19-selection being performed on day 4.
Finally, we have demonstrated that we can scale up
roduction sufﬁciently to treat adult patients at doses
f up to 107 cells/kg: allodepleted cells can be acti-
ated and transduced at 4  107 cells per ﬂask, and a
inimum of 8-fold return of CD19-selected ﬁnal cell
roduct can be obtained on day 8 post transduction, to
roduce at least 3  108 allodepleted gene-modiﬁed
ells per original ﬂask. The increased culture volume
s readily handled in additional ﬂasks or bags.
The allodepletion and iCasp9-modiﬁcation we de-
cribe should signiﬁcantly improve the safety of add-
ng back T cells, particularly after haploidentical stem
ell allografts. This should, in turn, enable greater
ose escalation, with a higher chance of producing a
oped for antileukemia effect. We will explore this
ossibility in a clinical study of our gene-modiﬁed
llodepleted T cells.
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